Mesuximide is an anticonvulsant pharmaceutical compound belonging to the succinimide class of antiepileptic agents. It has historically been used in the management of certain epileptic seizure disorders, particularly absence-type seizures.
Mesuximide is a specialized neurological pharmaceutical API relevant to anticonvulsant research and pharmaceutical development.
Mesuximide is a specialized antiepileptic API used in pharmaceutical research and formulation development. Its quality control requires careful assessment of identity, assay, related substances, residual solvents and other applicable pharmaceutical parameters.
CAS Number: 1269-77-8
Molecular Formula: C12H15NO2
Molecular Weight: 205.26 g/mol
Chemical Name: Mesuximide
Drug Class: Succinimide Anticonvulsant
Therapeutic Class: Antiepileptic
Therapeutic Area: Neurology
Molecule Type: Synthetic Small Molecule
Mesuximide belongs to the succinimide anticonvulsant group. Its anticonvulsant activity is associated with suppression of abnormal neuronal activity and reduction of seizure susceptibility.
Its pharmacological activity is particularly associated with mechanisms involved in absence seizures, although the precise molecular mechanism of mesuximide is not fully established.
Mesuximide has historically been associated with:
Mesuximide has historically been administered in oral pharmaceutical formulations, depending on the applicable product and regulatory market.
Mesuximide is handled as a solid pharmaceutical substance. Its exact appearance, crystalline characteristics and particle properties should be controlled according to the applicable API specification.
A controlled Mesuximide API manufacturing process may involve:
Typical Mesuximide API testing may include:
Store Mesuximide API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive moisture, heat and direct light.
Mesuximide is relevant to research involving:
Mesuximide is a succinimide-class anticonvulsant with CAS Number 1269-77-8, molecular formula C12H15NO2, and molecular weight 205.26 g/mol. It has historically been associated with the treatment of epilepsy, particularly absence-type seizures.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |